Treatment of Pulmonary Manifestations of Primary Immunodeficiency Diseases

  • Nahal Mansouri
  • Davood Mansouri


Pulmonary complications are the most common presentations in primary immunodeficiency diseases (PIDs). Treatment of pulmonary manifestations of PIDs varies depending on the underlying processes (e.g., humoral, cellular, combined immunodeficiencies) and etiologies (e.g., infectious, inflammatory, malignant, etc.). The management consists of:
  1. (a)

    Prophylactic treatments such as chronic antimicrobial therapy; appropriate vaccinations; immunoglobulin supplementation, mainly in humoral or combined humoral and cellular immunodeficiencies; or anti-inflammatory therapy in diseases with airway involvement

  2. (b)

    Therapeutic management such as appropriate antibiotic coverage for pulmonary infectious manifestations, bronchodilator therapy for obstructive lung disease, airway clearance devices in bronchiectasis, lung transplantation in few cases, and finally bone marrow transplantation as a more definitive therapy in some disorders

  3. (c)

    Strategies to improve symptoms and overall quality of life, for example, cough suppressants, supplemental oxygen therapy, pulmonary rehabilitation, and nutritional support. Here, we provide an overview of different therapeutic and prophylactic approaches based on the underlying immunologic process.



Primary immunodeficiency diseases Pulmonary manifestations Infections Interstitial lung disease Bronchiectasis Malignancy Immunoglobulin therapy 


  1. 1.
    Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–60. e4CrossRefGoogle Scholar
  2. 2.
    Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis. 2014;59(10):1462–70.CrossRefGoogle Scholar
  3. 3.
    Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348(24):2416–22.CrossRefGoogle Scholar
  4. 4.
    Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, et al. Long-term interferon-γ therapy for patients with chronic granulomatous disease. Clin Infect Dis. 2004;39(5):692–9.CrossRefGoogle Scholar
  5. 5.
    Margolis DM, Melnick DA, Ailing DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis. 1990;162(3):723–6.CrossRefGoogle Scholar
  6. 6.
    Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr. 1989;114(4):555–60.CrossRefGoogle Scholar
  7. 7.
    Langley JM, Dodds L, Fell D, Langley GR. Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990-2002. BMC Infect Dis. 2010;10(1):219.CrossRefGoogle Scholar
  8. 8.
    Lanternier F, Barbati E, Meinzer U, Liu L, Pedergnana V, Migaud M, et al. Inherited CARD9 deficiency in 2 unrelated patients with invasive Exophiala infection. J Infect Dis. 2015;211(8):1241–50.CrossRefGoogle Scholar
  9. 9.
    Mansouri D, Adimi P, Mirsaedi M, Mansouri N, Tabarsi P, Amiri M, et al. Primary immune deficiencies presenting in adults: seven years of experience from Iran. J Clin Immunol. 2005;25(4):385–91.CrossRefGoogle Scholar
  10. 10.
    Mansouri D, Adimi P, Mirsaeidi M, Mansouri N, Khalilzadeh S, Masjedi MR, et al. Inherited disorders of the IL-12-IFN-γ axis in patients with disseminated BCG infection. Eur J Pediatr. 2005;164(12):753–7.CrossRefGoogle Scholar
  11. 11.
    Obregon RG, Lynch DA, Kaske T, Newell JD, Kirkpatrick CH. Radiologic findings of adult primary immunodeficiency disorders: contribution of CT. Chest. 1994;106(2):490–5.CrossRefGoogle Scholar
  12. 12.
    McShane PJ, Naureckas ET, Tino G, Strek ME. Non–cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–56.CrossRefGoogle Scholar
  13. 13.
    Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1–i58.CrossRefGoogle Scholar
  14. 14.
    Di Renzo M, Pasqui A, Auteri A. Common variable immunodeficiency: a review. Clin Exp Med. 2004;3(4):211–7.CrossRefGoogle Scholar
  15. 15.
    Driessen GJ, Dalm VA, van Hagen PM, Grashoff HA, Hartwig NG, van Rossum AM, et al. Common variable immunodeficiency and idiopathic primary hypogammaglobulinemia: two different conditions within the same disease spectrum. Haematologica. 2013;98(10):1617–23.CrossRefGoogle Scholar
  16. 16.
    Panigrahi MK. Common variable immunodeficiency disorder-An uncommon cause for bronchiectasis. Lung India. 2014;31(4):394.CrossRefGoogle Scholar
  17. 17.
    Rose ME, Lang DM. Evaluating and managing hypogammaglobulinemia. Cleve Clin J Med. 2006;73(2):133. -7, 40, 43-4CrossRefGoogle Scholar
  18. 18.
    Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy. J Allergy Clin Immunol. 2006;117(4):S525–S53.CrossRefGoogle Scholar
  19. 19.
    Neves PC, Guerra M, Ponce P, Miranda J, Vouga L. Non-cystic fibrosis bronchiectasis. Interact Cardiovasc Thorac Surg. 2011;13(6):619–25.CrossRefGoogle Scholar
  20. 20.
    Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax. 2013;68(8):731–7.CrossRefGoogle Scholar
  21. 21.
    Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J. 2014;44(2):382–93.CrossRefGoogle Scholar
  22. 22.
    Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(7):577.CrossRefGoogle Scholar
  23. 23.
    Tay GT, Reid DW, Bell SC. Inhaled antibiotics in cystic fibrosis (CF) and non-CF bronchiectasis. Semin Respir Crit Care Med. 2015;36:267–86. Thieme Medical PublishersCrossRefGoogle Scholar
  24. 24.
    Eaton T, Young P, Zeng I, Kolbe J. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis. 2007;4(1):23–30.CrossRefGoogle Scholar
  25. 25.
    Main E, Grillo L, Rand S. Airway clearance strategies in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med. 2015;36:251–66. Thieme Medical PublishersCrossRefGoogle Scholar
  26. 26.
    Reeves EP, Molloy K, Pohl K, McElvaney NG. Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. Sci World J. 2012;2012:465230.CrossRefGoogle Scholar
  27. 27.
    Reeves EP, Williamson M, O'neill SJ, Greally P, McElvaney NG. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med. 2011;183(11):1517–23.CrossRefGoogle Scholar
  28. 28.
    O’donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest. 1998;113(5):1329–34.CrossRefGoogle Scholar
  29. 29.
    Haworth CS, Bilton D, Elborn JS. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir Med. 2014;108(10):1397–408.CrossRefGoogle Scholar
  30. 30.
    Tsang K, Tan K, Ho P, Ooi G, Ho J, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60(3):239–43.CrossRefGoogle Scholar
  31. 31.
    Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Libr. 2009;1:CD000996.Google Scholar
  32. 32.
    Maimon N, Lipton J, Chan C, Marras T. Macrolides in the treatment of bronchiolitis obliterans in allograft recipients. Bone Marrow Transplant. 2009;44(2):69.CrossRefGoogle Scholar
  33. 33.
    Feldman C. The use of antiinflammatory therapy and macrolides in bronchiectasis. Clin Chest Med. 2012;33(2):371–80.CrossRefGoogle Scholar
  34. 34.
    Tabarsi P, Mirsaeidi M, Karimi S, Banieghbal B, Mansouri N, Masjedi MR, et al. Lymphocytic bronchiolitis as presenting disorder in an undiagnosed adult patient with chronic granulomatous disease. Send to Iran J Allergy Asthma Immunol. 2007;6(4):219–21.Google Scholar
  35. 35.
    Cha S-I, Fessler MB, Cool CD, Schwarz MI, Brown KK. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J. 2006;28(2):364–9.CrossRefGoogle Scholar
  36. 36.
    Prasse A, Kayser G, Warnatz K. Common variable immunodeficiency-associated granulomatous and interstitial lung disease. Curr Opin Pulm Med. 2013;19(5):503–9.CrossRefGoogle Scholar
  37. 37.
    Tanaka N, Kim JS, Bates CA, Brown KK, Cool CD, Newell JD, et al. Lung diseases in patients with common variable immunodeficiency: chest radiographic, and computed tomographic findings. J Comput Assist Tomogr. 2006;30(5):828–38.CrossRefGoogle Scholar
  38. 38.
    Nicholson AG. Lymphocytic interstitial pneumonia and other lymphoproliferative disorders in the lung. Semin Respir Crit Care Med. 2001;22:409–22. Copyright© 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.:+ 1 (212) 584-4662.CrossRefGoogle Scholar
  39. 39.
    Chase NM, Verbsky JW, Hintermeyer MK, Waukau JK, Tomita-Mitchell A, Casper JT, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol. 2013;33(1):30–9.CrossRefGoogle Scholar
  40. 40.
    Boursiquot J-N, Gérard L, Malphettes M, Fieschi C, Galicier L, Boutboul D, et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol. 2013;33(1):84–95.CrossRefGoogle Scholar
  41. 41.
    Franxman TJ, Howe LE, Baker JR. Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency. J Clin Immunol. 2014;34(7):820–7.CrossRefGoogle Scholar
  42. 42.
    Thatayatikom A, Thatayatikom S, White AJ. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Ann Allergy Asthma Immunol. 2005;95(3):293–300.CrossRefGoogle Scholar
  43. 43.
    Kainulainen L, Varpula M, Liippo K, Svedström E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999;104(5):1031–6.CrossRefGoogle Scholar
  44. 44.
    Svobodova T, Mejstrikova E, Salzer U, Sukova M, Hubacek P, Matej R, et al. Diffuse parenchymal lung disease as first clinical manifestation of GATA-2 deficiency in childhood. BMC Pulm Med. 2015;15(1):8.CrossRefGoogle Scholar
  45. 45.
    Chin TW, Stiehm ER, Falloon J, Gallin JI. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease. J Pediatr. 1987;111(3):349–52.CrossRefGoogle Scholar
  46. 46.
    Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine. 2000;79(3):170–200.CrossRefGoogle Scholar
  47. 47.
    Siddiqui S, Anderson VL, Hilligoss DM, Abinun M, Kuijpers TW, Masur H, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis. 2007;45(6):673–81.CrossRefGoogle Scholar
  48. 48.
    Tafti SF, Tabarsi P, Mansouri N, Mirsaeidi M, Ghajar MAM, Karimi S, et al. Chronic granulomatous disease with unusual clinical manifestation, outcome, and pattern of inheritance in an Iranian family. J Clin Immunol. 2006;26(3):291–6.CrossRefGoogle Scholar
  49. 49.
    Freeman AF, Holland SM. The hyper-IgE syndromes. Immunol Allergy Clin North Am. 2008;28(2):277–91.CrossRefGoogle Scholar
  50. 50.
    Shapiro RS. Malignancies in the setting of primary immunodeficiency: implications for hematologists/oncologists. Am J Hematol. 2011;86(1):48–55.CrossRefGoogle Scholar
  51. 51.
    Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res. 2008;28(2B):1263–9.PubMedGoogle Scholar
  52. 52.
    Gatei M, Young D, Cerosaletti KM, Desai-Mehta A, Spring K, Kozlov S, et al. ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat Genet. 2000;25(1):115.CrossRefGoogle Scholar
  53. 53.
    Taylor A, Metcalfe J, Thick J, Mak Y. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996;87(2):423–38.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Cohen JM, Sebire NJ, Harvey J, Gaspar HB, Cathy C, Jones A, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood. 2007;110(6):2209–14.CrossRefGoogle Scholar
  55. 55.
    Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, et al. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol. 2009;124(6):1152–60. e12CrossRefGoogle Scholar
  56. 56.
    Hill A, Thompson R, Wallwork J, Stableforth D. Heart lung transplantation in a patient with end stage lung disease due to common variable immunodeficiency. Thorax. 1998;53(7):622–3.CrossRefGoogle Scholar
  57. 57.
    Yeatman M, McNeil K, Smith JA, Stewart S, Sharples LD, Higenbottam T, et al. Lung transplantation in patients with systemic diseases: an eleven-year experience at Papworth Hospital. J Heart Lung Transplant. 1996;15(2):144–9.PubMedGoogle Scholar
  58. 58.
    Kuo CY, Kohn DB. Gene therapy for the treatment of primary immune deficiencies. Curr Allergy Asthma Rep. 2016;16(5):39.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nahal Mansouri
    • 1
  • Davood Mansouri
    • 2
  1. 1.Department of Medicine, Division of Pulmonary and Critical Care MedicineBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Department of Infectious Disease and Clinical ImmunologyMassih Daneshvari Hospital, Shahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations